ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 777

A Unique Role For Galectin-9 In Angiogenesis and Inflammatory Arthritis

Martin O'Brien1, Qiang Shu2, Pei-Suen Tsou3, William Stinson4, Jeffrey H. Ruth3, Takeo Isozaki5, Alisa E. Koch6, David A. Fox5 and M. Asif Amin5, 1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 2Department of Internal Medicine, University of Michigan Medical School and Qilu Hospital of Shandong University, Ann Arbor, MI, 3Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 4Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 5Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 6VA Medical Service, Ann Arbor, MI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Angiogenesis, galectin and inflammatory arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I: Identifying Novel Factors that Facilitate Neovascularization and Cell Trafficking

Session Type: Abstract Submissions (ACR)

Background/Purpose: Galectin-9 (Gal-9) is a mammalian lectin which contributes to T-cell autoimmunity and tumor biology. Here, we examined the contribution of Gal-9 in angiogenesis and inflammatory arthritis, two critical components involved in the pathogenesis of rheumatoid arthritis (RA).

Methods: To determine the role of Gal-9 in angiogenesis in vitro, we performed human dermal microvascular endothelial cell (HMVEC) chemotaxis in modified Boyden chambers and Matrigel tube formation assays. We employed the mouse Matrigel plug angiogenesis assay to examine the involvement of Gal-9 in angiogenesis in vivo. Inhibitors and siRNA to signaling molecules for Gal-9 were also tested in these assays. We performed a local model of inflammation by injecting Gal-9 in the knees of C57/Bl6 wild type (wt) mice. HMVECs were stimulated with Gal-9 in the presence or absence of chemical inhibitors and Western blots were performed to investigate the phosphorylation of signaling molecules. We also examined the expression of Gal-9 in RA synovial tissue (ST) sections by performing immunohistochemistry.

Results: Gal-9 significantly induced HMVEC migration at 1µg/mL and 2µg/mL (P < 0.05), while signaling inhibitors of Erk1/2, p38, and c-Jun inhibited Gal-9-mediated HMVEC migration (P < 0.05). Gal-9 increased HMVEC Matrigel tube formation in vitro, another facet of angiogenesis, which was significantly reduced by the signaling inhibitors of Erk1/2, c-Jun, and p38 (P < 0.05). We confirmed our data by using siRNA directed against signaling intermediates. To examine the role of Gal-9 in angiogenesis in vivo, we performed Matrigel plug angiogenesis assays in mice. Gal-9 induced significantly higher (P < 0.05) hemoglobin, an indirect measure of angiogenesis, compared to phosphate buffered saline (PBS) injected plugs. Gal-9-mediated angiogenesis was attenuated in the plugs containing Jnk inhibitor, suggesting the importance of Jnk in Gal-9 induced angiogenesis in vivo. We found a marked increase in inflammation when wt mouse knees were injected with Gal-9 compared to PBS, suggesting that Gal-9 is a potent proinflammatory mediator. Gal-9-stimulated HMVECs showed a time-dependent increase in Jnk and Erk1/2 phosphorylation. We also found that Jnk is upstream of Erk1/2, as siRNA directed against Jnk decreased Gal-9-activated Erk1/2 phosphorylation in HMVECs. Immunohistochemical staining showed markedly higher expression of Gal-9 in blood vessels in RA compared to osteoarthritis ST sections.

Conclusion: Gal-9 mediates angiogenesis in vitro and in vivo via Erk1/2 and Jnk pathways. Gal-9 increases mouse knee circumference when injected intraarticularly. Our data suggest a novel role of Gal-9 in angiogenesis and inflammatory arthritis. Gal-9 may be a potential therapeutic target for angiogenesis-dependent diseases such as RA.


Disclosure:

M. O’Brien,
None;

Q. Shu,
None;

P. S. Tsou,
None;

W. Stinson,
None;

J. H. Ruth,
None;

T. Isozaki,
None;

A. E. Koch,

Eli Lilly and Company,

3;

D. A. Fox,
None;

M. A. Amin,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-unique-role-for-galectin-9-in-angiogenesis-and-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology